183 related articles for article (PubMed ID: 31529266)
1. Development, Optimization, and Evaluation In Vitro/In Vivo of Oral Liquid System for Synchronized Sustained Release of Levodopa/Benserazide.
Qu Y; Lai WL; Xin YR; Zhu FQ; Zhu Y; Wang L; Ding YP; Xu Y; Liu HF
AAPS PharmSciTech; 2019 Sep; 20(8):312. PubMed ID: 31529266
[TBL] [Abstract][Full Text] [Related]
2. A feasibility study of differential delivery of levodopa ester and benserazide using site-specific intestinal loops in rats.
Itoh S; Oo C
J Pharm Sci; 2010 Jan; 99(1):227-33. PubMed ID: 19455628
[TBL] [Abstract][Full Text] [Related]
3. Improved Bioavailability of Levodopa Using Floatable Spray-Coated Microcapsules for the Management of Parkinson's Disease.
Baek JS; Tee JK; Pang YY; Tan EY; Lim KL; Ho HK; Loo SCJ
Neuromolecular Med; 2018 Jun; 20(2):262-270. PubMed ID: 29696585
[TBL] [Abstract][Full Text] [Related]
4. Comparative bioavailability of 2 tablet formulations of levodopa/benserazide in healthy, fasting volunteers: a single-dose, randomized-sequence, open-label crossover study.
Keller GA; Czerniuk P; Bertuola R; Spatz JG; Assefi AR; Di Girolamo G
Clin Ther; 2011 Apr; 33(4):500-10. PubMed ID: 21635995
[TBL] [Abstract][Full Text] [Related]
5. Preparation and
Liu H; Xie X; Chen C; Firempong CK; Feng Y; Zhao L; Yin X
Drug Dev Ind Pharm; 2021 Mar; 47(3):394-402. PubMed ID: 33615926
[TBL] [Abstract][Full Text] [Related]
6. Comparative single- and multiple-dose pharmacokinetics of levodopa and 3-O-methyldopa following a new dual-release and a conventional slow-release formulation of levodopa and benserazide in healthy volunteers.
Crevoisier C; Monreal A; Metzger B; Nilsen T
Eur Neurol; 2003; 49(1):39-44. PubMed ID: 12464717
[TBL] [Abstract][Full Text] [Related]
7. Evaluation and optimization of preparative variables for controlled-release floating microspheres of levodopa/carbidopa.
Choudhary H; Agrawal AK; Malviya R; Yadav SK; Jaliwala YA; Patil UK
Pharmazie; 2010 Mar; 65(3):194-8. PubMed ID: 20383939
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic-pharmacodynamic interaction between nebicapone and controlled-release levodopa/benserazide: a single-center, Phase I, double-blind, randomized, placebo-controlled, four-way crossover study in healthy subjects.
Nunes T; Machado R; Rocha JF; Fernandes-Lopes C; Costa R; Torrão L; Loureiro AI; Falcão A; Vaz-da-Silva M; Wright L; Almeida L; Soares-da-Silva P
Clin Ther; 2009 Oct; 31(10):2258-71. PubMed ID: 19922897
[TBL] [Abstract][Full Text] [Related]
9. Development and characterization of gastro-floating sustained-release capsule with improved bioavailability of levodopa.
Yuan H; Zhang Z; Hu L
Drug Deliv Transl Res; 2023 Jan; 13(1):9-17. PubMed ID: 35661106
[TBL] [Abstract][Full Text] [Related]
10. [Effectiveness of slow release L-DOPA/benserazide in treatment of end-of-dose akinesia in Parkinson disease].
Eichhorn TE; Schrag A; Trenkwalder C; Selzer R; Kohnen R; Oertel WH; Poewe W
Nervenarzt; 1995 Dec; 66(12):933-41. PubMed ID: 8584079
[TBL] [Abstract][Full Text] [Related]
11. Mucuna pruriens in Parkinson Disease: A Kinetic-Dynamic Comparison With Levodopa Standard Formulations.
Contin M; Lopane G; Passini A; Poli F; Iannello C; Guarino M
Clin Neuropharmacol; 2015; 38(5):201-3. PubMed ID: 26366963
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the pharmacokinetics of an oral extended-release capsule formulation of carbidopa-levodopa (IPX066) with immediate-release carbidopa-levodopa (Sinemet(®)), sustained-release carbidopa-levodopa (Sinemet(®) CR), and carbidopa-levodopa-entacapone (Stalevo(®)).
Hsu A; Yao HM; Gupta S; Modi NB
J Clin Pharmacol; 2015 Sep; 55(9):995-1003. PubMed ID: 25855267
[TBL] [Abstract][Full Text] [Related]
13. Multi-Drug-Loaded Microcapsules with Controlled Release for Management of Parkinson's Disease.
Baek JS; Choo CC; Qian C; Tan NS; Shen Z; Loo SC
Small; 2016 Jul; 12(27):3712-22. PubMed ID: 27253884
[TBL] [Abstract][Full Text] [Related]
14. Report: Preparation of levodopa/carbidopa compound drug resins.
Liu H; Ding H; Zhang D; Fengsi -; Sun C
Pak J Pharm Sci; 2018 Jan; 31(1):205-211. PubMed ID: 29348105
[TBL] [Abstract][Full Text] [Related]
15. Optimizing levodopa pharmacokinetics: intestinal infusion versus oral sustained-release tablets.
Nyholm D; Askmark H; Gomes-Trolin C; Knutson T; Lennernäs H; Nyström C; Aquilonius SM
Clin Neuropharmacol; 2003; 26(3):156-63. PubMed ID: 12782919
[TBL] [Abstract][Full Text] [Related]
16. Comparative single- and multiple-dose pharmacokinetics of levodopa and 3-O-methyldopa following a new dual-release and a conventional slow-release formulation of levodopa and benserazide in healthy subjects.
Gasser UE; Crevoisier C; Ouwerkerk M; Lankhaar G; Dingemanse J
Eur J Pharm Biopharm; 1998 Sep; 46(2):223-8. PubMed ID: 9795070
[TBL] [Abstract][Full Text] [Related]
17. Single-dose studies of a slow-release preparation of levodopa and benserazide (Madopar HBS) in Parkinson's disease.
Marion MH; Stocchi F; Malcolm SL; Quinn NP; Jenner P; Marsden CD
Eur Neurol; 1987; 27 Suppl 1():54-8. PubMed ID: 3322837
[TBL] [Abstract][Full Text] [Related]
18. Release profile comparison and stability of diltiazem-resin microcapsules in sustained release suspensions.
Junyaprasert VB; Manwiwattanakul G
Int J Pharm; 2008 Mar; 352(1-2):81-91. PubMed ID: 18061381
[TBL] [Abstract][Full Text] [Related]
19. Continuous wavelet and derivative transforms for the simultaneous quantitative analysis and dissolution test of levodopa-benserazide tablets.
Dinç E; Kaya S; Doganay T; Baleanu D
J Pharm Biomed Anal; 2007 Aug; 44(4):991-5. PubMed ID: 17512691
[TBL] [Abstract][Full Text] [Related]
20. [Benefits of a new galenic form of levodopa and benserazide in the treatment of patients with Parkinson disease].
Dessibourg CA; Gachoud JP
Praxis (Bern 1994); 1995 Oct; 84(43):1235-8. PubMed ID: 7481341
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
